We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.28% |
| 2 | Real Estate | 2.09% |
| 3 | Miscellaneous | 1.37% |
| 4 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$234B
| $137M | 5.36% |
616,539
+60,600
| +11% | +$14.1M |
|
2
Johnson & Johnson
JNJ
$646B
| $119M | 4.68% |
721,779
| – | – |
|
3
Gilead Sciences
GILD
$181B
| $118M | 4.63% |
1,533,884
-26,000
| -2% | -$2.07M |
|
|
4
Regeneron Pharmaceuticals
REGN
$81.8B
| $116M | 4.54% |
161,418
+18,365
| +13% | +$14.2M |
|
5
Vertex Pharmaceuticals
VRTX
$137B
| $112M | 4.38% |
318,043
-12,300
| -4% | -$4.14M |
|
|
6
Eli Lilly
LLY
$1.05T
| $100M | 3.92% |
213,352
-75,565
| -26% | -$31.7M |
|
7
UnitedHealth
UNH
$353B
| $99.5M | 3.89% |
206,961
-27,212
| -12% | -$13.3M |
|
|
8
Merck
MRK
$366B
| $84M | 3.29% |
728,154
+176,032
| +32% | +$20M |
|
9
AbbVie
ABBV
$451B
| $73.5M | 2.88% |
545,629
+34,030
| +7% | +$4.99M |
|
10
Biogen
BIIB
$32.3B
| $70.6M | 2.76% |
247,943
+7,017
| +3% | +$2.09M |
|
11
AstraZeneca
AZN
$252B
| $69.9M | 2.74% |
488,338
-7,994
| -2% | -$1.18M |
|
12
Illumina
ILMN
$32.6B
| $63.2M | 2.47% |
346,414
-11,411
| -3% | -$2.31M |
|
13
Abbott
ABT
$195B
| $60.2M | 2.36% |
552,455
-71,400
| -11% | -$7.61M |
|
14
Pfizer
PFE
$159B
| $59.6M | 2.33% |
1,624,476
-150,600
| -8% | -$5.86M |
|
15
Thermo Fisher Scientific
TMO
$230B
| $51.6M | 2.02% |
98,987
+5,282
| +6% | +$2.85M |
|
16
Elevance Health
ELV
$85.5B
| $50.7M | 1.98% |
114,070
| – | – |
|
17
Moderna
MRNA
$55.1B
| $41.8M | 1.63% |
343,695
+21,478
| +7% | +$2.87M |
|
18
Boston Scientific
BSX
$67.9B
| $35.6M | 1.39% |
657,790
+91,800
| +16% | +$4.79M |
|
19
Danaher
DHR
$152B
| $34.3M | 1.34% |
161,093
+41,875
| +35% | +$8.86M |
|
20
Medtronic
MDT
$117B
| $30.3M | 1.19% |
344,417
-100
| -0% | -$8.61K |
|
21
Idexx Laboratories
IDXX
$43.7B
| $29.4M | 1.15% |
58,595
| – | – |
|
22
DexCom
DXCM
$34.3B
| $29.4M | 1.15% |
228,747
| – | – |
|
|
23
Bristol-Myers Squibb
BMY
$136B
| $29.3M | 1.15% |
458,498
-205,298
| -31% | -$13.8M |
|
24
Intuitive Surgical
ISRG
$132B
| $28.7M | 1.12% |
83,980
-28,700
| -25% | -$8.68M |
|
25
Alnylam Pharmaceuticals
ALNY
$31.7B
| $27.2M | 1.06% |
143,214
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCB
FCFS
BWM
Tekla Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.
Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.
- Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
- Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
- Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
- Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
- Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
- Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.